Regarding tyrosine kinase inhibitors, a phase 1-2 clinical trial 154 evaluated selpercatinib in patients with medullary thyroid cancer with a RET mutation and patients with RET fusions thyroid cancer. This evidence concerns the gene RET and medullary thyroid gland carcinoma.